Management of Retroperitoneal High-grade Serous Carcinoma of Unknown Origin: A Case Report

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2024 Mar 11

PMID 38464925

Authors

Wen-Lin Hsieh

Dah-Ching Ding

Affiliations

Soon will be listed here.

Abstract

Background: Retroperitoneal high-grade serous carcinoma (HGSC) of unknown origin is a sporadic tumor that can originate from ovarian cancer. Herein, we report the case of a woman with retroperitoneal HGSC of unknown origin and describe how she was diagnosed and treated.

Case Summary: A 71-year-old female presented with the tumor marker CA125 elevated to 1041.9 U/mL upon a regular health examination. Computed tomography revealed retroperitoneal lymph node enlargement. Subsequently, positron emission tomography scanning revealed lesions with increased F-18 fluorodeoxyglucose uptake at the nodes. As a result, she underwent laparoscopic lymph node resection, and pathology revealed metastatic adenocarcinoma with CK7(+), PAX8(+), WT1(+), PR(-), and p53 mutational loss of expression, indicating that the origin may be from the adnexa. The patient was admitted to our ward and underwent laparoscopic staging; however, the pathological results were negative. Under the suspicion of retroperitoneal HGSC of unknown origin, chemotherapy and targeted therapy were initiated. Tumor marker levels decreased after treatment.

Conclusion: We present a case of HGSC of unknown origin managed using retroperitoneal lymphadenectomy, staging surgery, chemotherapy, and targeted therapy.

References

Berek J, Renz M, Kehoe S, Kumar L, Friedlander M . Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:61-85. PMC: 9298325. DOI: 10.1002/ijgo.13878. View

Gallan A, Antic T . Benign müllerian glandular inclusions in men undergoing pelvic lymph node dissection. Hum Pathol. 2016; 57:136-139. DOI: 10.1016/j.humpath.2016.07.003. View

Gadducci A, Guarneri V, Peccatori F, Ronzino G, Scandurra G, Zamagni C . Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019; 12(1):9. PMC: 6348631. DOI: 10.1186/s13048-019-0484-6. View

Kohada Y, Teishima J, Hattori Y, Kurimura Y, Fujii S, Sadahide K . Serous adenocarcinoma of retroperitoneum: a case report. Int Cancer Conf J. 2019; 6(4):154-157. PMC: 6498288. DOI: 10.1007/s13691-017-0296-8. View

Chae Y, Saleem N, Roh Y, Bilal H, Viveiros P, Sukhadia B . Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review. BMC Cancer. 2019; 19(1):748. PMC: 6668104. DOI: 10.1186/s12885-019-5934-4. View

Otsuka I, Honma K . FDG PET/CT in Primary Retroperitoneal Serous Carcinoma. Clin Nucl Med. 2023; 48(7):625-626. DOI: 10.1097/RLU.0000000000004692. View

Otsuka I . Primary Retroperitoneal Carcinomas: New Insights into Pathogenesis and Clinical Management in Comparison with Ovarian Carcinomas and Carcinoma of Unknown Primary. Cancers (Basel). 2023; 15(18). PMC: 10526425. DOI: 10.3390/cancers15184614. View

Tokai H, Nagata Y, Taniguchi K, Matsumura N, Kitasato A, Tokunaga T . The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. Surg Case Rep. 2017; 3(1):117. PMC: 5702287. DOI: 10.1186/s40792-017-0394-z. View

Wang Y, Sessine M, Zhai Y, Tipton C, McCool K, Kuick R . Lineage tracing suggests that ovarian endosalpingiosis does not result from escape of oviductal epithelium. J Pathol. 2019; 249(2):206-214. PMC: 7457448. DOI: 10.1002/path.5308. View

10.

Homsi M, Dadlani A, Khazai B, Anendaga C, Bakhru S, Flaherty F . Diffuse abdominal and pelvic endosalpingiosis: A case report. Radiol Case Rep. 2022; 17(10):3515-3518. PMC: 9352425. DOI: 10.1016/j.radcr.2022.06.075. View

11.

Otsuka I . Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. Int J Mol Sci. 2021; 22(9). PMC: 8122889. DOI: 10.3390/ijms22094409. View

12.

Narayanan P, Sahdev A . The role of F-FDG PET CT in common gynaecological malignancies. Br J Radiol. 2017; 90(1079):20170283. PMC: 5963379. DOI: 10.1259/bjr.20170283. View

13.

Matulonis U, Sood A, Fallowfield L, Howitt B, Sehouli J, Karlan B . Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061. PMC: 7290868. DOI: 10.1038/nrdp.2016.61. View

14.

Engbersen M, Van Driel W, Lambregts D, Lahaye M . The role of CT, PET-CT, and MRI in ovarian cancer. Br J Radiol. 2021; 94(1125):20210117. PMC: 9327775. DOI: 10.1259/bjr.20210117. View

15.

Boyarskikh U, Gulyaeva L, Avdalyan A, Kechin A, Khrapov E, Lazareva D . Spectrum of Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer. Front Oncol. 2020; 10:1103. PMC: 7378769. DOI: 10.3389/fonc.2020.01103. View

16.

Myriokefalitaki E, Luqman I, Potdar N, Brown L, Steward W, Moss E . Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. Arch Gynecol Obstet. 2015; 293(4):709-20. DOI: 10.1007/s00404-015-3975-8. View

17.

Zhang Y, Cao L, Nguyen D, Lu H . TP53 mutations in epithelial ovarian cancer. Transl Cancer Res. 2019; 5(6):650-663. PMC: 6320227. DOI: 10.21037/tcr.2016.08.40. View